Connection

DAVID ROWLEY to Stromal Cells

This is a "connection" page, showing publications DAVID ROWLEY has written about Stromal Cells.
Connection Strength

3.452
  1. Stromal TGF-? signaling induces AR activation in prostate cancer. Oncotarget. 2014 Nov 15; 5(21):10854-69.
    View in: PubMed
    Score: 0.420
  2. Reprogramming the tumor stroma: a new paradigm. Cancer Cell. 2014 Oct 13; 26(4):451-2.
    View in: PubMed
    Score: 0.417
  3. The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation. 2011 Nov-Dec; 82(4-5):200-10.
    View in: PubMed
    Score: 0.331
  4. Keratinocyte-derived chemokine induces prostate epithelial hyperplasia and reactive stroma in a novel transgenic mouse model. Prostate. 2009 Mar 01; 69(4):373-84.
    View in: PubMed
    Score: 0.283
  5. Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology. 2008 Jul; 72(1):205-13.
    View in: PubMed
    Score: 0.264
  6. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma. Oncogene. 2008 Jan 17; 27(4):450-9.
    View in: PubMed
    Score: 0.252
  7. Regulation of rat prostate stromal cell myodifferentiation by androgen and TGF-beta1. Prostate. 2004 Feb 15; 58(3):299-307.
    View in: PubMed
    Score: 0.199
  8. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res. 2003 Oct 15; 9(13):4792-801.
    View in: PubMed
    Score: 0.195
  9. What might a stromal response mean to prostate cancer progression? Cancer Metastasis Rev. 1998-1999; 17(4):411-9.
    View in: PubMed
    Score: 0.130
  10. Histologic features of stromogenic carcinoma of the prostate (carcinomas with reactive stroma grade 3). Hum Pathol. 2017 05; 63:202-211.
    View in: PubMed
    Score: 0.123
  11. RUNX1 is essential for mesenchymal stem cell proliferation and myofibroblast differentiation. Proc Natl Acad Sci U S A. 2014 Nov 18; 111(46):16389-94.
    View in: PubMed
    Score: 0.104
  12. The reactive stroma microenvironment and prostate cancer progression. Endocr Relat Cancer. 2012 Dec; 19(6):R187-204.
    View in: PubMed
    Score: 0.091
  13. Characterization of tumor-derived pancreatic stellate cells. J Surg Res. 2009 Nov; 157(1):96-102.
    View in: PubMed
    Score: 0.072
  14. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 2005 Oct 01; 65(19):8887-95.
    View in: PubMed
    Score: 0.056
  15. Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model. Cancer Res. 2003 Sep 15; 63(18):5859-65.
    View in: PubMed
    Score: 0.048
  16. Glutathione S-transferase pi is upregulated in the stromal compartment of hormone independent prostate cancer. Prostate. 2003 Jul 01; 56(2):98-105.
    View in: PubMed
    Score: 0.048
  17. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res. 2002 Nov 01; 62(21):6021-5.
    View in: PubMed
    Score: 0.046
  18. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res. 2002 Sep; 8(9):2912-23.
    View in: PubMed
    Score: 0.045
  19. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res. 2002 Jun 01; 62(11):3298-307.
    View in: PubMed
    Score: 0.044
  20. In vitro dorsal root ganglia and human prostate cell line interaction: redefining perineural invasion in prostate cancer. Prostate. 2001 Nov 01; 49(3):213-23.
    View in: PubMed
    Score: 0.043
  21. Transforming growth factor-beta1 induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle cells. Endocrinology. 1998 Aug; 139(8):3569-77.
    View in: PubMed
    Score: 0.034
  22. Jagged1 upregulation in prostate epithelial cells promotes formation of reactive stroma in the Pten null mouse model for prostate cancer. Oncogene. 2017 02 02; 36(5):618-627.
    View in: PubMed
    Score: 0.029
  23. Reactive stroma in the prostate during late life: The role of microvasculature and antiangiogenic therapy influences. Prostate. 2015 Oct; 75(14):1643-61.
    View in: PubMed
    Score: 0.027
  24. Beta-2 microglobulin is mitogenic to PC-3 prostatic carcinoma cells and antagonistic to transforming growth factor beta 1 action. Cancer Res. 1995 Feb 15; 55(4):781-6.
    View in: PubMed
    Score: 0.027
  25. FGFR1-WNT-TGF-? signaling in prostate cancer mouse models recapitulates human reactive stroma. Cancer Res. 2014 Jan 15; 74(2):609-20.
    View in: PubMed
    Score: 0.025
  26. Genes upregulated in prostate cancer reactive stroma promote prostate cancer progression in vivo. Clin Cancer Res. 2014 Jan 01; 20(1):100-9.
    View in: PubMed
    Score: 0.024
  27. Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res. 2009 Jun 15; 15(12):3979-89.
    View in: PubMed
    Score: 0.018
  28. Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol. 2007 Nov; 38(11):1611-20.
    View in: PubMed
    Score: 0.016
  29. Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res. 2006 May 15; 66(10):5159-64.
    View in: PubMed
    Score: 0.015
  30. Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section. Am J Pathol. 2006 May; 168(5):1405-12.
    View in: PubMed
    Score: 0.015
  31. Neuroepithelial interactions in prostate cancer are enhanced in the presence ofprostatic stroma. Urology. 2003 Apr; 61(4):870-5.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.